Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. develops clinical-stage protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins. Company news centers on the rinvatercept (KER-065) program for neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, as well as elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
Recurring updates include clinical data presentations, research collaborations, business highlights, financial results, and licensing economics tied to Takeda. Keros also reports governance changes, corporate presentations, portfolio prioritization, and capital actions such as its completed common-stock tender offer and capital return program.
Keros Therapeutics (KROS) reported its fourth quarter and full year 2022 financial results, revealing a net loss of $29.7 million for Q4 and $104.7 million for the entire year, significantly up from $6.9 million and $58.7 million in 2021, respectively. The increase is attributed to heightened research and development costs, particularly for the Phase 2 trials of KER-050 targeting myelodysplastic syndromes and myelofibrosis. Keros maintained a strong cash position of $279.0 million as of December 31, 2022, sufficient to fund operations into Q3 2025. The company outlined several key milestones for 2023, including expanded trials for KER-050 and KER-047.
Keros Therapeutics, Inc. (Nasdaq: KROS), a biopharmaceutical company, announced that its President and CEO Jasbir S. Seehra, Ph.D., will participate in a fireside chat at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 11:10 a.m. Eastern time. The event will provide insights into Keros’ innovative treatments for hematological, pulmonary, and cardiovascular disorders. A live audio webcast can be accessed here, with an archived replay available on Keros’ website for up to 90 days post-event.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced participation in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. President and CEO Jasbir S. Seehra, Ph.D., will represent the company.
A live audio webcast of the event will be available here, with an archived replay accessible on Keros' website for up to 90 days post-event. Keros focuses on novel treatments for hematological, pulmonary, and cardiovascular disorders, including lead candidates KER-050, KER-047, and KER-012.
Keros Therapeutics presented new data from its ongoing Phase 2 clinical trials during the 2022 ASH Annual Meeting, focusing on KER-050 for myelodysplastic syndromes (MDS) and myelofibrosis (MF), and KER-047 for iron-refractory iron deficiency anemia (IRIDA). Results showed a 51.7% erythroid response rate in MDS patients receiving KER-050, with treatment well-tolerated and no serious adverse events reported. Initial data for KER-047 indicated potential iron redistribution. The company maintains a focus on developing treatments for hematological disorders with high unmet medical needs.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that President and CEO Jasbir S. Seehra, Ph.D., will participate in upcoming fireside chats at the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.
Piper Sandler Conference: November 29, 10:00 a.m. ET. Live audio webcast available here.
Evercore ISI Conference: December 1, 8:50 a.m. ET. Live audio webcast available here.
Keros Therapeutics, Inc. (KROS) announced promising preclinical results for RKER-012, a novel treatment for pulmonary arterial hypertension (PAH). The findings, presented at the American Heart Association 2022 Scientific Sessions, show that RKER-012 improved cardiac and pulmonary function in a rat model of PAH. The treatment significantly reduced inflammatory and fibrotic markers, indicating potential for treating not just PAH but other inflammatory diseases. KER-012's development targets crucial pathways involved in fibrosis and cardiac hypertrophy.
Keros Therapeutics (KROS) announced the acceptance of five abstracts for presentation at the 64th American Society of Hematology Annual Meeting, scheduled for December 10-13, 2022. The presentations include preliminary results from Phase 2 trials for KER-050, aimed at treating myelodysplastic syndromes and myelofibrosis, and KER-047 for iron-refractory iron deficiency anemia. CEO Jasbir S. Seehra highlighted this as an opportunity to share important updates and anticipates releasing additional efficacy data for KER-050 by mid-December.
Keros Therapeutics (KROS) reported a net loss of $23.5 million for Q3 2022, up from $20.3 million in Q3 2021, primarily due to increased R&D efforts. The company spent $21.0 million on R&D, a rise of $6.2 million year-over-year, while general administrative expenses also increased to $6.9 million. As of September 30, 2022, Keros held $239.4 million in cash, bolstered by recent share sales, ensuring funding into Q1 2025. The company is advancing its clinical programs and anticipates a Phase 2 trial for KER-012 in pulmonary arterial hypertension, with more data expected by year-end.
Keros Therapeutics (KROS) announced preliminary clinical data from the Part 2 multiple ascending dose portion of its Phase 1 trial of KER-012, presented at the American Society of Bone and Mineral Research annual meeting on September 11, 2022. The results indicate that KER-012 effectively inhibits activin signaling, evidenced by a 52% reduction in follicle-stimulating hormone levels and significant increases in bone-specific alkaline phosphatase markers. No clinically meaningful changes were noted in hemoglobin or red blood cells. Keros plans to initiate a Phase 2 trial for KER-012 in pulmonary arterial hypertension patients in early 2023.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced participation in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 PM ET. CEO Jasbir S. Seehra, Ph.D., and CFO Keith Regnante will discuss the company's innovative treatments aimed at hematological, pulmonary, and musculoskeletal disorders. A live audio webcast will be available, and an archived replay can be accessed for 90 days on Keros' website. Keros focuses on developing therapies like KER-050, KER-047, and KER-012 for various medical needs.